# Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

> **NCT01034787** · PHASE2 · COMPLETED · sponsor: **AHS Cancer Control Alberta** · enrollment: 11 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** CP-675,206

## Key facts

- **NCT ID:** NCT01034787
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-17
- **Primary completion:** 2017-08-08
- **Final completion:** 2017-08-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01034787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01034787, "Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01034787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*